newsfilter
← Latest News
Earnings Call Transcripts·

Q3 2026 IRIDEX Earnings Conference Call - IRIDEX CORP

  • Financial Performance:

    • Q3 2026 total revenue was $10.2 million, a decline from $12.5 million in Q3 2025, driven primarily by lower international retina and glaucoma probe orders.
    • Gross margin improved to 42.4% year-over-year (up from 32.1%), including a $0.8 million one-time inventory write-down in the prior year; pro forma margin excluding that charge was 38.7% (a 370 bps improvement).
    • Net loss narrowed to $1.4 million ($0.08 EPS) compared to $1.6 million ($0.09 EPS) in the prior year period.
    • Non-GAAP adjusted EBITDA loss widened to $0.6 million from a $0.1 million loss in the prior year.
    • Operating expenses remained flat at $5.5 million compared to $5.4 million in the prior year.
    • Cash and cash equivalents ended the quarter at $3.7 million (down from $4.7 million in Q2), with $1.0 million net cash used in operating activities, largely due to a $1.6 million inventory buildup for safety stock.
    • Retina product revenue fell to $5.1 million from $6.7 million, while Cyclo-G6 family revenue decreased to $3.2 million from $3.5 million; other revenue was $1.9 million from $2.2 million.
  • Guidance and Future Outlook:

    • Full-year 2026 revenue guidance was lowered to $46–$48 million (excluding Middle East revenue), reflecting inventory normalization and regulatory delays.
    • Full-year adjusted operating expenses (excluding D&A and stock-based compensation) are expected to be $19.0–$19.5 million.
    • No specific financial guidance provided for 2027, but management anticipates 2027 will be more profitable due to realized cost savings, lower cost of goods, and contract manufacturing transitions.
    • Q4 2026 revenue is expected to range between $11.5 million and $13.5 million, driven by safety stock conversion, deferred Japan shipments, and seasonal trends.
    • Management expects to achieve Q4 adjusted EBITDA positivity if revenue hits the higher end of the guidance range, though full-year 2026 will remain loss-making.
    • Long-term goals include entering 2027 with a streamlined product portfolio, a lower-cost base, and a cash-generating business model.
  • Business Segments and Product Lines:

    • Glaucoma (Cyclo-G6): U.S. Pascal system placements increased to 8 from 7 year-over-year; U.S. probe ASPs remain elevated; U.S. G6 probe volume was 6,900 units (steady YoY). International probe volume dropped to 11,900 units (from 14,900) due to distributor inventory digestion.
    • Retina: U.S. Pascal revenue surged ~50% YoY, but international performance was weak due to deferrals in Japan, regulatory delays in India, and pricing pressure in Europe.
    • Strategic Shifts: Manufacturing relocation to San Jose is complete, yielding ~$600k in annual rent savings; transition to third-party contract manufacturing for major products is on track for completion in 2026.
    • Portfolio Rationalization: Management is conducting a strategic review to streamline product lines, focusing only on profitable revenue streams and potentially exiting non-profitable regions or product lines.
  • Market and Competitive Landscape:

    • U.S. Glaucoma: Benefiting from favorable Medicare LCD reimbursement changes, MedScout targeting, and two-year clinical data supporting earlier adoption of microPulse TLT.
    • Europe/EMEA: Facing aggressive pricing pressure from competitors (e.g., Artibex in glaucoma) and regulatory delays regarding new Pascal MDR certification (expected H1 2027).
    • Asia: China faces stagnant activity due to economic weakness and slow tender cycles; Japan experienced volatility due to pre-relocation inventory stocking.
    • Middle East: Activity weighed down by conflict; revenue from this region is excluded from forecasts.
    • Market Position: Management asserts strong market share growth in the U.S. for the Pascal system despite international headwinds.
  • Risks and Challenges:

    • Regulatory: Delays in MDR certification for new products in key markets (Germany, Austria, India) are restricting sales and causing distributor hesitation.
    • Geopolitical: Ongoing conflict in the Middle East and economic instability in China are dampening international demand.
    • Supply Chain/Logistics: Manufacturing address changes necessitated safety stock building, temporarily tying up cash flow and delaying international shipments.
    • Competitive: Intense pricing pressure in international retina and glaucoma markets is eroding market share and revenue potential.
    • Revenue Volatility: International distributor ordering patterns and inventory burn-off periods create unpredictable quarterly results.
  • Management Commentary and Tone:

    • Tone: Cautious but determined; leadership acknowledged Q3 results were "disappointing" and "below expectations" but emphasized structural progress and a clear path to 2027 profitability.
    • Confidence: High confidence in U.S. glaucoma growth and the long-term value proposition of micropulse therapy; clear resolve to prioritize profitability over top-line growth in unprofitable regions.
    • Strategic Focus: Decisive actions are being taken to retool the business, including cost reductions, contract manufacturing, and portfolio rationalization to achieve sustainable profitability.
  • Analyst Questions and Answers:

    • Retina Outlook: Asked about organic growth expectations for Retina; management cited persistent weakness in China ($3.6M orders vs $4M last year) and volatility in Japan, expecting Q4 to still reflect double-digit declines YoY.
    • Share Gains: Confirmed gaining share in the U.S. (50% Pascal growth) but facing challenges internationally due to distributor waiting for regulatory approvals.
    • G6 Probes: Q4 expected to show sequential growth in probe volume, though year-over-year growth may be negative due to prior inventory building; system placements expected to increase both sequentially and YoY.
    • Profitability Metrics: Q4 could be EBITDA positive if revenue hits the high end of guidance; long-term margin improvements will come from facility savings (allocated to COGS), stopping sales of low-margin products, and further OPEX reductions.
  • Other Key Points:

    • Manufacturing relocation to San Jose was completed on October 5th; TUV and BSI audits are passed, awaiting final certificates.
    • Safety stock built to cover "blackout periods" during regulatory re-registration is now converting to revenue, aiding cash flow recovery.
    • The company is evaluating moving more operations overseas to further reduce costs.
    • All outstanding international probe backorders from Q2 for China and Japan have been fulfilled.
    • The Middle East region was removed from guidance earlier in the year due to regional instability.
Company
IRIDEX CORP
Keywords
IRIDEX CORP